Let's restore
immune health.
A first-in-class approach to autoimmune disease, led by drug hunters with a combined century of discovery experience.
.svg)
.svg)
We are focused on the autoimmune indications where the biology is most validated and the unmet need is largest.
3.4M worldwide.
Plus ~40 interferonopathies with upregulated type I interferon signaling.
2.8M IBD total.
7M worldwide.
2.8M worldwide.
A prominent neurological autoimmune disease our mechanism is positioned to address.
What if we could obliterate pro-inflammation signals, instead of just muting them?
A new way to modulate a vital node in a well-precedented family of inflammatory signaling pathways.
Our molecular mechanism generates a new field of chemical opportunities for revolutionary oral medicines leveraging this biology.
.svg)
Today's Standard
vs
What We Are Building
The biology is de-risked. The remaining question is chemistry, and chemistry is our team's native language.
Clinically validated biology
A signaling family long implicated in autoimmune disease. Protective human variants confirm that dampening a key signaling node reduces disease risk.
Structural advantage
A classic drug-binding geometry with built-in selectivity. Unique molecular features that translate directly into fewer off-target effects.
.png)
Chemistry match
A proven chemical-biology approach, matched to the target. The site is non-obvious — yet unmistakably druggable once found.
.png)
Team expertise
Over a hundred years of combined drug discovery experience, assembled from our CEO's career-long network of the people he trusts most.
After three decades of drug hunting, from a Pfizer R&D executive seat to the presidency of the Trudeau Institute, Atsuo stepped away to return to his roots, and assembled the colleagues he trusts most from across that career.
Atsuo Kuki, PhD
The only Pfizer executive to serve on both the global chemical synthesis and global drug design councils, bridging chemistry and computation across the company's R&D. Led 700+ scientists and technicians at NCI's flagship technology division in Frederick MD, and launched a national initiative against oncogenic K-RAS-driven cancers. Former President of the Trudeau Institute, an immunobiology research institute. Renowned for leading drug discovery teams that take on hard targets.
.png)
Led multiple drug discovery programs across oncology, CNS, and immunology. Co-founded a biotech that achieved the first-ever clinical PoC for a computationally retargeted drug. Conceived the central and previously hidden insights behind Mintellium’s technology and new medicines
.png)
Serial entrepreneur with over twenty years commercializing advanced technology. Former CEO of NanoPin, SVP of Polarization Solutions, and GM of Celgene / NanoOpto.
.png)
Seasoned executive leader with a strong record of value creation, leading research portfolios, building high‑performing teams, and forging strategic partnerships. Shaped the scientific narrative for the $52M oversubscribed IPO at Cognition Therapeutics, delivering 100+ investor presentations.
.png)
Built world-class chemistry infrastructure at Pfizer producing 250,000+ molecules annually. Trained under a Nobel laureate in harnessing novel chemistry for biological objectives.
Dr. Ilia Ichetovkin is a globally recognized leader in Precision Medicine and CDx, with more than 25 years of experience advancing products from early scientific concept through global regulatory approval, holding strategic leadership roles at numerous prominent and emerging biotechnology companies
A secure moat around a new mechanism.
From first filing to fortified composition and methods coverage.
Pharma has shown strong, continued appetite for autoimmune. Mintellium is being built for it.
a single year, across the indications we
target.
A validated disease mechanism. A first-in-class molecular approach. A fully-owned IP package. A de-risked clinical path. This is the profile pharma pays for, and it is the profile we are building.
Let's have a conversation.
.svg){kind=logo}